These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 25916431)

  • 21. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.
    Tritos NA; Biller BM
    Pituitary; 2017 Feb; 20(1):129-135. PubMed ID: 27631335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma Agouti-Related Protein Levels in Acromegaly and Effects of Surgical or Pegvisomant Therapy.
    Freda PU; Reyes-Vidal C; Jin Z; Pugh M; Panigrahi SK; Bruce JN; Wardlaw SL
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5453-5461. PubMed ID: 31361303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ACROSTUDY: the first 5 years.
    Trainer PJ
    Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S19-24. PubMed ID: 19684052
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.
    Herman-Bonert VS; Zib K; Scarlett JA; Melmed S
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2958-61. PubMed ID: 10946911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
    Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant.
    Drake WM; Loureiro RA; Parkinson C; Monson JP; Besser GM; Trainer PJ
    Eur J Endocrinol; 2005 Jan; 152(1):47-51. PubMed ID: 15762186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis.
    Tritos NA; Chanson P; Jimenez C; King D; Jönsson PJ; Klibanski A; Biller BM
    Eur J Endocrinol; 2017 Feb; 176(2):213-220. PubMed ID: 27932529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis.
    Biering H; Saller B; Bauditz J; Pirlich M; Rudolph B; Johne A; Buchfelder M; Mann K; Droste M; Schreiber I; Lochs H; Strasburger CJ;
    Eur J Endocrinol; 2006 Feb; 154(2):213-20. PubMed ID: 16452533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDY.
    Grottoli S; Bianchi A; Bogazzi F; Bona C; Carlsson MO; Colao A; Dassie F; Giampietro A; Gomez R; Granato S; Maffei P; Pivonello R; Prencipe N; Ragonese M; Urbani C; Cannavò S
    J Endocrinol Invest; 2022 Aug; 45(8):1535-1545. PubMed ID: 35359232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly.
    Lindberg-Larsen R; Møller N; Schmitz O; Nielsen S; Andersen M; Orskov H; Jørgensen JO
    J Clin Endocrinol Metab; 2007 May; 92(5):1724-8. PubMed ID: 17341562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful treatment of resistant acromegaly with a growth hormone receptor antagonist.
    Drake WM; Parkinson C; Akker SA; Monson JP; Besser GM; Trainer PJ
    Eur J Endocrinol; 2001 Oct; 145(4):451-6. PubMed ID: 11581004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly.
    Trainer PJ; Drake WM; Perry LA; Taylor NF; Besser GM; Monson JP
    J Clin Endocrinol Metab; 2001 Jul; 86(7):2989-92. PubMed ID: 11443156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
    Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pegvisomant: current and potential novel therapeutic applications.
    Thankamony GN; Dunger DB; Acerini CL
    Expert Opin Biol Ther; 2009 Dec; 9(12):1553-63. PubMed ID: 19916734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experience from the Argentine Pegvisomant Observational Study: preliminary data.
    García Basavilbaso N; Guitelman M; Nagelberg A; Stalldecker G; Carabelli A; Bruno O; Danilowitz K; Manavela M; Mallea Gil S; Ballarino C; Guelman R; Katz D; Fidalgo S; Leal R; Fideleff H; Servidio M; Bruera D; Librandi F; Chervin A; Vitale M; Basso A
    Front Horm Res; 2010; 38():42-49. PubMed ID: 20616494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of monotherapy by pegvisomant, a growth hormone receptor antagonist, in Japanese patients with acromegaly.
    Shimatsu A; Nagashima M; Hashigaki S; Ohki N; Chihara K
    Endocr J; 2016 Apr; 63(4):337-47. PubMed ID: 26796763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term treatment with pegvisomant for acromegaly: a 10-year experience.
    Ramos-Leví AM; Bernabeu I; Álvarez-Escolá C; Aller J; Lucas T; de Miguel P; Rodríguez-Cañete L; Sampedro-Núñez MA; Halperin I; Puig-Domingo M; Marazuela M
    Clin Endocrinol (Oxf); 2016 Apr; 84(4):540-50. PubMed ID: 26662620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment with high doses of pegvisomant in 56 patients with acromegaly: experience from ACROSTUDY.
    van der Lely AJ; Jönsson P; Wilton P; Åkerblad AC; Cara J; Ghigo E
    Eur J Endocrinol; 2016 Oct; 175(4):239-45. PubMed ID: 27401863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy.
    Marazuela M; Lucas T; Alvarez-Escolá C; Puig-Domingo M; de la Torre NG; de Miguel-Novoa P; Duran-Hervada A; Manzanares R; Luque-Ramírez M; Halperin I; Casanueva FF; Bernabeu I
    Eur J Endocrinol; 2009 Apr; 160(4):535-42. PubMed ID: 19147599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pegvisomant treatment in acromegaly in clinical practice: Final results of the French ACROSTUDY (312 patients).
    Barraud S; Caron P; Raingeard I; Lefebvre H; Raverot G; Cortet-Rudelli C; Desailloud R; Henocque R; Brault Y; Brue T; Chanson P; Delemer B
    Ann Endocrinol (Paris); 2021 Dec; 82(6):582-589. PubMed ID: 34256010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.